ArticleCureus2026
Biliary Tract Carcinoma: Real-World Evidence in a Developing Country.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Biliary tract carcinoma (BTC) is underreported. This study describes the clinical characteristics and survival outcomes of BTC patients at six institutions in Colombia. Methods This is an observational, retrospective, multicenter, and real-life study of BTC patients. Baseline demographics, clinical characteristics, and treatment patterns were collected. A Kaplan-Meier analysis was used to estimate overall survival (OS), event-free survival (EFS), and progression-free survival (PFS). Multivariable Cox proportional hazards regression analyses for OS were performed in the overall cohort and in patients who received first-line treatment. Results A total of 214 BTC patients were included of which 136 were women (63.6%). Gallbladder carcinoma accounted for n=102 (47.7%), extrahepatic cholangiocarcinoma for n=59 (27.5%), and intrahepatic cholangiocarcinoma for n=53 (24.8%). Radical surgery was performed in 127 (59.3%) patients, 34 (26.8%) of whom remained relapse-free. First-line treatment for advanced disease was given to 116 patients (54.2%). Gemcitabine alone or in combination was used in 102 (87.9%) patients. The median EFS and OS were 16.4 months (95%CI: 12.3-20.6) and 21.5 months (95%CI: 14.2-28.8), respectively. Among patients initially diagnosed with metastatic disease, the median OS was 7.9 months (95%CI: 6.9-8.9). In 55 patients treated with gemcitabine-cisplatin as first-line therapy, the median OS was 9.6 months (95%CI: 5.5-13.7). In multivariable analysis, Eastern Cooperative Oncology Group performance status ≥2 and CA 19-9 >100U/mL were independently associated with worse OS. Conclusions In Colombia, patients with BTC face a poor prognosis, even in the early stages. Survival with gemcitabine-cisplatin for advanced disease is lower than that reported in clinical trials. These real-world data inform expectations for physicians and patients in Colombia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.